Amit Sachdev serves as Executive Vice President and Chief Patient and External Affairs Officer at Vertex Pharmaceuticals Incorporated, where he leads the company's global efforts in patient engagement, access to therapies, policy advocacy, and external partnerships. In this role, he champions patient-centric strategies to ensure equitable access to Vertex's innovative treatments, particularly for cystic fibrosis, sickle cell disease, and other rare diseases. Sachdev oversees initiatives that bridge the gap between groundbreaking science and real-world patient needs, fostering collaborations with patient advocacy groups, payers, and regulators to accelerate therapy adoption and address unmet needs. With over two decades of experience in the pharmaceutical industry, Sachdev has built a distinguished career focused on transforming patient engagement from a peripheral function to a core business driver. Prior to joining Vertex in 2021, he was Senior Vice President and Global Head of Patient, Health, and Site Engagement at Pfizer, where he spearheaded patient advisory boards and digital health platforms that influenced drug development pipelines. Earlier roles at Bristol-Myers Squibb as Vice President of Global Patient Engagement and at Genentech honed his expertise in rare disease strategy and stakeholder alignment. Sachdev's achievements include pioneering data-driven patient journey mapping, which has optimized clinical trial recruitment and post-approval support across multiple therapies. A recognized leader in healthcare policy, he has testified before U.S. Congress on gene therapy access and co-authored influential publications on patient inclusion in R&D. At Vertex, his leadership has expanded global patient support programs, notably enhancing access to CFTR modulators in emerging markets and advancing equitable solutions for CRISPR-based therapies like Casgevy.